E. Ohman J or Asset Management AB Sells 24,163 Shares of Natera, Inc. $NTRA

Key Points

• E. Ohman Jor Asset Management AB cut its Natera stake by 88.2%, selling 24,163 shares and retaining 3,232 shares valued at approximately $877,000. Institutional investors still own 99.9% of Natera’s outstanding stock.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above estimates, while its adjusted loss of $0.47 per share slightly beat expectations.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and a $301.90 price target; recent targets range from $300 to $375. The stock opened at $312.72, near its 12-month high of $326.03.

E. Ohman J or Asset Management AB lowered its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 88.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,232 shares of the medical research company's stock after selling 24,163 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Natera were worth $877,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NTRA. Handelsbanken Fonder AB increased its position in Natera by 29.1% during the second quarter. Handelsbanken Fonder AB now owns 207,800 shares of the medical research company's stock worth $56,407,000 after acquiring an additional 46,800 shares during the period. Everhart Financial Group Inc. bought a new stake in Natera in the 2nd quarter valued at about $254,000. Teamwork Financial Advisors LLC bought a new stake in Natera in the 2nd quarter valued at about $2,936,000. FNY Investment Advisers LLC acquired a new position in shares of Natera during the 2nd quarter worth approximately $59,000. Finally, Elevation Wealth Partners LLC acquired a new position in shares of Natera during the 2nd quarter worth approximately $30,000. Institutional investors own 99.90% of the company's stock.

Natera Trading Down 1.8%

Shares of NASDAQ:NTRA opened at $312.72 on Wednesday. The firm has a 50 day moving average of $258.02 and a 200-day moving average of $224.81. Natera, Inc. has a 12 month low of $152.62 and a 12 month high of $326.03. The stock has a market capitalization of $45.08 billion, a PE ratio of -229.94 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.82%. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.74) EPS. On average, research analysts predict that Natera, Inc. will post -1.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on NTRA shares. Canaccord Genuity Group set a $375.00 price target on shares of Natera in a research report on Friday. Morgan Stanley reiterated an "overweight" rating and issued a $355.00 price target on shares of Natera in a research note on Monday. TD Cowen increased their price target on Natera from $325.00 to $340.00 and gave the stock a "buy" rating in a research report on Friday. Robert W. Baird set a $348.00 price objective on Natera in a research note on Friday. Finally, Evercore reaffirmed an "outperform" rating and issued a $300.00 price objective on shares of Natera in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $301.90.

Insiders Place Their Bets

In other news, insider John Fesko sold 295 shares of Natera stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $267.99, for a total value of $79,057.05. Following the transaction, the insider owned 183,774 shares in the company, valued at approximately $49,249,594.26. This trade represents a 0.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the business's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer directly owned 99,897 shares of the company's stock, valued at $26,611,561.83. This trade represents a 2.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock valued at $41,330,968 over the last ninety days. Company insiders own 5.05% of the company's stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source